Patent intelligence · US
US 10548879
(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
Patent details — US 10548879
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 4, 2020
- Expiration
- Jan 30, 2040
- Applicant
- Theravance Biopharma R&D IP, LLC
- Claims
- 20
- CPC classes
- A61K, A61K31/421, A61K45/06, A61K47/12
Quick answer
US 10548879 ((2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid) is held by Theravance Biopharma R&D IP, LLC. Status: granted. Granted Feb 4, 2020. Expires Jan 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/421, A61K45/06, A61K47/12, A61K9/4816, A61K9/4825
More from Theravance Biopharma R&D IP, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 10548879?
US 10548879 ((2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid) is held by Theravance Biopharma R&D IP, LLC. Status: granted. Granted Feb 4, 2020. Expires Jan 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10548879?
Theravance Biopharma R&D IP, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 10548879 expire?
Our index shows an expiration date of Jan 30, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.